Indeed, a variant of CD47 with improved affinity for SIRPα had a synergistic effect when used in combination with tumor-specific monoclonal Abs to ameliorate phagocytosis of tumor cells in vitro (209), although its antitumoral effects in vivo have not been evaluated (Figure 5C). This evidence concerns the gene SIRPA and neoplasm.